Influence of Intensive Lipid-lowering on FFRCT (The FLOW-PROMOTE Study)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT04737408
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 120 participants
- Sponsor
- Bjarne Linde Noergaard
- Registry
-
NCT04737408
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Unknown status
Technical summary
Registry record NCT04737408. Randomized; no masking; primary purpose prevention. Start 2020-05-13 (actual); primary completion 2023-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Influence of Intensive Lipid-lowering on FFRCT (The FLOW-PROMOTE Study)
- Acronym
- FlowPromote
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Rosuvastatin 40mg
- Lead sponsor
- Bjarne Linde Noergaard
Record details
- Record id
cardio:ct-nct04737408- Content hash
b6acca96ea1521bee3397eb7d7f507a29d8f6c115bde9146e6423675a3256c48